Home Interviews Chordate Medical advances to final phase of exit strategy

Chordate Medical advances to final phase of exit strategy

Chordate

Chordate Medical advances to final phase of exit strategy

17 October, 2024

Chordate Medical has a clear goal of executing an exit and has now appointed Partner International Switzerland as an advisor to find a buyer and finalize the exit strategy. A key part of this strategy is the company’s work to establish proof of concept in selected target markets for the migraine treatment Ozilia. Recently, the company has made significant progress in Saudi Arabia, where the migraine treatment has received market approval.

BioStock interviews Chordate Medical’s CEO, Anders Weilandt, regarding the exit strategy and market advancements.

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev